By this approach, we consistently observed in all the three cohorts that the level of SPP1 and ALCAM mRNA expression enables the discrimination of good vs bad outcome in all ‘high-risk’ breast cancer patients showing low or no ESR1 and HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.